Cazenove Capital Management’s Harvard Bioscience HBIO Stock Holding History

Cazenove Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$4.49K	Buy	+126	New	+$4.82K	﹤0.01%	199

Other funds holding HBIO

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

FCAM

F&C Asset Management Edinburgh, Scotland, United Kingdom $7.92B AUM 24.35% 1-Year Est. Return

HSA

Hussman Strategic Advisors Ellicott City, Maryland $434M AUM 19.64% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return

Cazenove Capital Management's HBIO Position: Q2 2013 in Review

Cazenove Capital Management opened a new position in Harvard Bioscience (HBIO) in Q2 2013: 126 shares worth $4.49K. The stake represents ﹤0.01% of the portfolio and ranks #199 among its holdings.

79 funds tracked by Wall St. Rank hold HBIO as of Q2 2013.

Cazenove Capital Management held 126 shares of Harvard Bioscience worth $4.49K as of Q2 2013.
Harvard Bioscience was a new Cazenove Capital Management position in Q2 2013.
Harvard Bioscience made up ﹤0.01% of Cazenove Capital Management's portfolio in Q2 2013, its #199 holding.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2013.

Based on Cazenove Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.